Pathological changes of biochemical, hematological and coagulation analyses in patients with COVID-19 disease

Published: 22 April 2024
Abstract Views: 420
PDF: 180
HTML: 54
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


The identification of patients with poor prognosis and early detection of COVID-19 disease complications are made possible by pathological analyses of routine hematological, coagulation, and biochemical tests. Interpreting analyses needs to be done within the framework of each patient’s unique clinical picture. It’s also critical to keep an eye on changes at the individual parameter level. From May 20th, 2021, to March 30th, 2024, a comprehensive search of literature was carried out using international databases, such as PubMed, Embase, Web of Science, Scopus, and the Cochrane Library, in compliance with the PRISMA guidelines. The research question was formulated using the PICO strategy. The following terms were used: biochemical parameters in COVID-19, hematological parameters in COVID-19, blood coagulation parameters in COVID-19, indicators of inflammation, and indicators of tissue damage in SARS-CoV-2. Routine hematological, coagulation, and biochemical tests are primarily used to monitor the progression of the disease and the effectiveness of treatment rather than being utilized for the established diagnosis of COVID-19 due to their low specificity. Molecular genetics and immunological techniques should be used to determine the COVID-19 disease diagnosis.



PlumX Metrics


Download data is not yet available.

Citations Coronavirus arrives in Kosovo, the first two cases are confirmed, a 20-year-old Italian and an elderly person. 2020. Available from:
Hoti I. Qeveria e Kosovës zyrtarisht mbyll COVID-19 [The Government of Kosovo officially closes COVID-19]. 2023. Available from:
Haroon Hasanat HA, Mohammed Saghir SA, Al-Areefi M. Hematological and biochemical parameter changes among healthy individuals infected with COVID-19 according to sex and age: A hospital based study. Electron J Gen Med 2023;20:em527. DOI:
Thompson S, Bohn MK, Mancini N, et al. IFCC interim guidelines on biochemical/hematological monitoring of COVID-19 patients. Clin Chem Lab Med 2020;58:2009-16. DOI:
Kurstjens S, van der Horst A, Herpers R, et al. Rapid identification of SARS-CoV-2-infected patients at the emergency department using routine testing. Clin Chem Lab Med 2020;58. DOI:
Khourssaji M, Chapelle V, Evenepoel A, et al. A biological profile for diagnosis and outcome of COVID-19 patients. Clin Chem Lab Med 2020;58:2141-50. DOI:
Debuc B, Smadja DM. Is COVID-19 a new hematologic disease? Stem Cell Rev Rep 2021;17:4-8. DOI:
Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19. Am J Hematol 2020;95:834-47. DOI:
El Aidouni G, Merbouh M, El Kaouini A, et al. Lymphopenia in COVID-19: a single center retrospective study of 589 cases. Ann Med Surg (Lond) 2021;69:02816.
Niu J, Sareli C, Mayer D, et al. Lymphopenia as a predictor for adverse clinical outcomes in hospitalized patients with COVID-19: a single center retrospective study of 4485 cases. J Clin Med 2022;11:700 DOI:
Ndieugnou Djabgang N, Peluso L, Talamonti M, et al. Eosinopenia in COVID-19 patients: a retrospective analysis. Microorganisms 2020;8:1929. DOI:
Outh R, Boutin C, Gueudet P, et al. Eosinopenia <100/μL as a marker of active COVID-19: An observational prospective study. J Microbiol Imunol Infect 2021;54:61-8. DOI:
Anurag A, Jha PK, Kumar A. Differential white blood cell count in the COVID-19: A cross-sectional study of 148 patients. Diabetes Metab Syndr 2020;14:2099-102. DOI:
Taghavi-Farahabadi M, Mahmoudi M, Hashemi SM, Namaki S. Neutrophils to lymphocytes ratio and the prognosis of the COVID-19 patients. Immunoregulation 2020;3:89-96.
Rong N, Wei X, Liu J. The role of neutrophil in COVID-19: positive or negative. Innate Immun 2024;16:80-95. DOI:
Zhang Y, Zeng X, Jiao Y, et al. Mechanisms involved in the development of thrombocytopenia in patients with COVID-19. Thromb Res 2020;193:10-5. DOI:
Kichloo A, Dettloff K, Aljadah M, et al. COVID-19 and hypercoagulability: a review. Clin Appl Thromb Hemost 2020;26:1-9. DOI:
Xu SW, Ilyas I, Weng JP. Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacol Sin 2023;44:695-709. DOI:
Qu R, Ling Y, Zhang YH, et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J Med Virol 2020;92:1533-41. DOI:
Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020;135:2033-40. DOI:
Hakobyan N, Ilerhunmwuwa N, Wasifuddin M, et al. COVID-19-associated disseminated intravascular coagulopathy presenting as inferior st-segment elevation myocardial infarction. Cureus 2023;15:e39308. DOI:
Katrien MJ. Devreese.COVID-19–related laboratory coagulation findings. Int Soc Lab Hematol 2021;43:36-42. DOI:
Ceriz T, Lagarteira J, Alves SR, et al. Disseminated intravascular coagulation in COVID-19 setting: a clinical case description. Cureus 2023;15:e39941. DOI:
Araya S, Mamo MA, Tsegay YG, et al. Blood coagulation parameter abnormalities in hospitalized patients with confirmed COVID-19 in Ethiopia. PLoS ONE 2021;16:e0252939. DOI:
Sui J, Noubouossie DF, Gandorta S, Cao L. Elevated plasma fibrinogen is associated with excessive inflammation and disease severity in COVID-19 patients. Front Cell Microbiol 2021;11. DOI:
Lin J, Yan H, Chen H, et al. COVID-19 and coagulation dysfunction in adults: a systematic review and metaanalysis. J Med Virol 2021;93:934-44. DOI:
Yao Y, Cao J, Wang Q, et al. D-dimer as a biomarker for disease severitv and mortality in COVID-19 patients: a case control study. J Intensive Care 2020;8:49. DOI:
Short S, Gupta S, Brenner S, et al. D-dimer and death in critically ill patients with Coronavirus disease 2019. Crit Care Med 2021;E500-E511. DOI:
Zeng F, Huang Y, Guo Y, et al. Association of inflammatory markers with the severity of COVID-19: a metaanalysis. Int J Infect Dis 2020;96:467-74. DOI:
Bray C, Bell LN, Liang H, et al. Erythrocyte sedimentation rate and C-reactive protein measurements and their relevance in clinical medicine. WMJ 2016;115:317-21.
Li F, He M, Zhou M, et al. Association of C-reactive protein with mortality in COVID-19 patients: a secondary analysis of a cohort study. Sci Rep 2023;13:20361. DOI:
Avihai B, Sundel EP, Lee E, et al. CRP Monitoring in Early Hospitalization: Implications for Predicting Outcomes in Patients with COVID-19. Pathogens 2023;12:1315. DOI:
Cheng L, Li H, Li Let al. Ferritin in the coronavirus disease 2019 (COVID-19): a systematic review and metaanalysis. J Clin Lab Anal 2020:34:e23618. DOI:
Kaushal K, Kaur H, Sarma P, et al. Serum ferritin as a predictive biomarker in COVID-19. A systematic review, meta analysis and meta-regression analysis. J Crit Care 2022;67:172-81. DOI:
Dolci A, Robbiano C, Aloisio E, et al. Searching for a role of procalcitonin determination in COVID-19: a study on a selected cohort of hospitalized patients. Clin Chem Lab Med 2021;59:433-40. DOI:
Cowman K, Rossi J, Gendlina I, et al. Elucidating the role of procalcitonin as a biomarker in hospitalized COVID-19 patients. Diagn Microbiol Infect Dis 2022;103:115721. DOI:
Lu Y, Sun K, Guo S, et al. Early Warning indicators of severe COVID-19: a single-center study of cases from Shanghai, China. Front Med (Lausanne) 2020;7:432. DOI:
Wang Q, Cheng J, Shang J, et al. Clinical value of laboratory indicators for predicting disease progression and death in patients with COVID-19: a retrospective cohort study. BMJ Open 2021;11:e043790. DOI:
Han Y, Zhang H, Mu S, et al. Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study. Aging 2020;12:11245-58. DOI:
Boregowda U, Aloysius MM, Perisetti A, et al. Serum activity of liver enzymes is associated with higher mortality in COVID-19: a systematic review and meta-analysis. Front Med 2020;7:431. DOI:
Vidal-Cevallos P, Higuera-De-La-Tijera F, Chávez-Tapia NC, et al. Lactate-dehydrogenase associated with mortality in hospitalized patients with COVID-19 in Mexico: a multi-centre retrospective cohort study. Ann Hepatol 2021;24. DOI:
Yaluri N, Stančáková Yaluri A, Žeňuch P, et al. Cardiac biomarkers and their role in identifying increased risk of cardiovascular complications in COVID-19 patients. Diagnostics (Basel) 2023;13:2508. DOI:
Caro-Codón J, Rey JR, Buño A, et al. Characterization of NT-proBNP in a large cohort of COVID-19 patients. Eur J Heart Fail 2021;23:456-64. DOI:
Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system. Circ Res 2020;126.45. Akhmerov A, Marban E. COVID-19 and the heart. Circ Res 2020;126:1443-55. DOI:
Taheri M, Bahrami A, Habibi P, Nouri F. A review on the serum electrolytes and trace elements role in the pathophysiology of COVID-19. Biol Trace Elem Res 2020:8:1-7. DOI:
Sjöström A, Rysz S, Sjöström H, Höybye C. Electrolyte and acid-base imbalance in severe COVID-19. Endocr Connect 2021;10:805-14. DOI:

How to Cite

Gashi, Z., & Kadrija, M. (2024). Pathological changes of biochemical, hematological and coagulation analyses in patients with COVID-19 disease. Italian Journal of Medicine, 18(2).